ID   AMOC-2
AC   CVCL_C830
SY   AMOC2; Aichi Medical university Ovarian Carcinoma-2
DR   Wikidata; Q54749812
RX   PubMed=2794621;
RX   PubMed=9433040;
CC   Population: Japanese.
CC   Characteristics: Established from a third generation xenograft established in BALB/c nu/nu mice.
CC   Doubling time: 21.5-26.4 hours (PubMed=9433040).
CC   Derived from site: In situ; Ovary; UBERON=UBERON_0000992.
DI   NCIt; C7550; Ovarian serous adenocarcinoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Female
AG   60Y
CA   Cancer cell line
DT   Created: 22-10-12; Last updated: 29-06-23; Version: 11
CH   CVCL_AT98 ! AMOC-2 Subclone #10
CH   CVCL_AT99 ! AMOC-2 Subclone #11
CH   CVCL_AT95 ! AMOC-2 Subclone #2
CH   CVCL_AT96 ! AMOC-2 Subclone #4
CH   CVCL_AT97 ! AMOC-2 Subclone #6
//
RX   PubMed=2794621;
RA   Yabushita, Hiromitsu
RA   Ueno, Naoki
RA   Sawaguchi, Keizo
RA   Higuchi, Kazuyoshi
RA   Noguchi, Masayoshi
RA   Ishihara, Minoru
RT   "Establishment and characterization of a new human cell-line (AMOC-2)
RT   derived from a serous adenocarcinoma of ovary.";
RL   Nihon Sanka Fujinka Gakkai Zasshi 41:888-894(1989).
//
RX   PubMed=9433040; DOI=10.1111/j.1447-0756.1997.tb00878.x;
RA   Yabushita, Hiromitsu
RA   Noguchi, Masayoshi
RA   Nakanishi, Masami
RT   "Emergence of an irreversible differentiated subclone from the poorly
RT   differentiated ovarian adenocarcinoma cell line AMOC-2 treated with
RT   sodium butyrate.";
RL   J. Obstet. Gynaecol. Res. 23:493-502(1997).
//